Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Operating Expenses for 16 consecutive years, with $20.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 15.78% to $20.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.5 million, a 19.2% decrease, with the full-year FY2024 number at $103.2 million, up 7.1% from a year prior.
  • Operating Expenses was $20.9 million for Q3 2025 at Altimmune, down from $22.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $33.7 million in Q4 2023 to a low of $15.7 million in Q1 2021.
  • A 5-year average of $23.9 million and a median of $23.0 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 108.7% in 2021, then dropped 26.11% in 2024.
  • Altimmune's Operating Expenses stood at $27.3 million in 2021, then decreased by 15.69% to $23.0 million in 2022, then skyrocketed by 46.45% to $33.7 million in 2023, then decreased by 26.11% to $24.9 million in 2024, then decreased by 16.11% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Operating Expenses are $20.9 million (Q3 2025), $22.9 million (Q2 2025), and $21.8 million (Q1 2025).